Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by toniZ1on Aug 13, 2023 5:27am
84 Views
Post# 35585790

RE:RE:RE:AGM in sept

RE:RE:RE:AGM in sept haha still derma injector hopes ;-) indeed does not look like Shiseido buys em out, hopefully we will find out this year. If that 's not the case they might get some money paid for damages... On the other hand why did Shiseido ran a 2nd trail if they see no value in the tec?! 

The derma injector story is nothing of value from my point of view. Even if this device gets released, which I doubt, its nothing where you can expect a sudden huge demand and even more unlikly high profits. 

Simply their hair loss therapy is where the potential is for a huge demand/profits, as it always has been. If this potential can't be translated into reality there is simply no value in Replicel.

Even the YOFOTO story looks like a dead end, seems the progress here is zero.

Hopefully the AGM date is the final one....  
<< Previous
Bullboard Posts
Next >>